Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

December 24th 2024

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

December 23rd 2024

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

December 23rd 2024

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

December 23rd 2024

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC

December 22nd 2024

Aparna Parikh, MD, discussed novel agents that are currently at play in the mutated, metastatic colorectal cancer treatment field.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

December 20th 2024

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

December 20th 2024

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

December 20th 2024

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.

Uproleselan Plus Chemo Fails to Improve OS in R/R AML in China

December 20th 2024

Uproleselan plus chemotherapy did not improved overall survival in relapsed/refractory acute myeloid leukemia.

Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm

December 20th 2024

John Mascarenhas, MD, discusses navtemadlin's mechanism of action and its potential to shift the myelofibrosis treatment landscape

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

December 19th 2024

Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.

NX-5948 Receives FDA Fast Track Designation for R/R Waldenström Macroglobulinemia

December 19th 2024

The FDA granted fast track designation to NX-5948 for Waldenstrom macroglobulinemia that is relapsed/refractory to at least 2 lines of therapy.

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

December 19th 2024

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

December 19th 2024

Venetoclax-based treatment was associated with poorer outcomes in CLL previously treated with a BTK inhibitor and naive to chemotherapy.

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 18th 2024

The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

December 18th 2024

Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma

December 18th 2024

Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma

December 17th 2024

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC

December 17th 2024

Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.